Skip to main content
SpringerLink
Log in

Palliative Therapies in Elderly Cancer Patients

  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Palliative therapy in elderly cancer patients deserves special attention because of differences between young and elderly cancer patients. In elderly patients, the treatment produces more adverse effects and the disease is cured less frequently, but the prognosis is usually better than in young patients with cancer.

In the elderly population, cancer is seen more frequently than in the young population, yet elderly patients are less frequently included in trials. It is obvious that the results obtained from the treatment of young cancer patients do not necessarily apply to elderly cancer patients. The existing lack of formal data for the management of elderly cancer patients justifies 5 distinctive steps: collection of individual information; review of the available and appropriate knowledge; definition and specification of treatment goals; selection of treatment tools; and assessment of outcome. Following these steps will lead to coordination of oncology and palliative medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Porzsolt F, Haug H-U. Nützt oder schadet die adjuvante Immuntherapie? MMW 1989; 131: 130–3

    Google Scholar 

  2. Zylka-Melhorn V. Deficiencies in medical services [in German]. Dtsch Arzteblatt 1993; 46: B2245–B2246

    Google Scholar 

  3. Subcommittee on Health and Long-term Care of the Select Committee on Aging. Quackery: a $10 billion scandal. House of Representatives, 98th congress, 2nd session, 1984. Committee Publication no.: 98-435

  4. Wynne H, Cope L, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301

    PubMed  CAS  Google Scholar 

  5. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359–89

    PubMed  CAS  Google Scholar 

  6. Lindemann RD. Changes in renal function and aging: implications for treatment. Drugs Aging 1992; 2: 423–31

    Google Scholar 

  7. Platt D. Pharmaka-Interaktionen bei geriatrischen Patienten. Bayer Int 1990; 10: 8–12

    Google Scholar 

  8. Kinzel T, Feleppa V. Minimizing the side effects of cancer chemotherapy in senior patients. Drugs Aging 1992; 2: 137–45

    PubMed  CAS  Google Scholar 

  9. Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1986; 8: 249–55

    PubMed  CAS  Google Scholar 

  10. Montamat S, Cusack B, Vestal R. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303–9

    PubMed  CAS  Google Scholar 

  11. Platt D, editor. Drugs and aging. Berlin: Springer, 1986

    Google Scholar 

  12. Nolan L, O’Malley K. Prescribing for the elderly. J Am Geriatr Soc 1988; 36: 142–9

    PubMed  CAS  Google Scholar 

  13. Gurwitz JH, Avorn JH. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66

    PubMed  CAS  Google Scholar 

  14. Yancik R, Ries LG. Cancer in the aged: an epidemiologic perspective on treatment issues. Cancer 1991; 68: 2502–10

    PubMed  CAS  Google Scholar 

  15. Platt D, editor. Biologie des Alterns. Berlin: Walter de Gruyter, 1991

    Google Scholar 

  16. Miller RA. Gerontology as oncology: research on aging as the key to understanding of cancer. Cancer 1991; 68: 2496–501

    PubMed  CAS  Google Scholar 

  17. Holmes FF, Wilson J, Smith-Blesch K, et al. Biology of cancer and aging. Cancer 1991; 68: 2525–6

    PubMed  CAS  Google Scholar 

  18. Dohm G, Kaatsch P, Kolles H, et al. Erkrankungshaufigkeit und Uberlebenschancen bei Krebs: Ergebnisse des Saarlandischen Krebsregisters und des bundesweiten Registers für bösartige Erkrankungen im Kindesalter. Schriftenreihe des Bundesministeriums für Gesundheit, Band 2. Baden-Baden: Nomos Verlagsgesellschaft, 1991

    Google Scholar 

  19. Bertz J, Schon D, Casper W, et al. Vergleich der Krebssterblichkeit in den alten Bundeslandern der Bundesrepublik Deutschland und der ehemaligen DDR. Berlin: Institut für Sozialmedizin und Epidemiologie des Bundesgesundheitsamtes, 1992. SozEp-Hefte 5/1991

  20. Wilmanns W, Sauer H. Zytostatika-Therapie. In: Platt D, editor. Pharmakotherapie und Alter: ein Leitfaden für die Praxis. Berlin: Springer Verlag, 1988: 191–204

    Google Scholar 

  21. Kruse W. Arzeimittelnebenwirkungen — häufige Komplikationen. Geriatrische Praxis 1990; 11: 35–41

    Google Scholar 

  22. Platt D. Pharmakokinetik und-Dynamik. In: Platt D, editor. Biologie des Alterns. Berlin: Walter de Gruyter, 1991, 305–14

    Google Scholar 

  23. Sauer H. Zytostatische Therapie. In: Wilmanns W, Huhn D, Wilms K, editors. Internistische Onkologie. Stuttgart: Thieme, Stuttgart, New York; 1994: 141–86

    Google Scholar 

  24. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 335: 1020–2

    PubMed  CAS  Google Scholar 

  25. Dixon JM. Treatment of elderly patients with breast cancer: tamoxifen alone is no longer justified. BMJ 1992; 304: 996–7

    PubMed  CAS  Google Scholar 

  26. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. JAMA 1992; 268: 57–62

    PubMed  CAS  Google Scholar 

  27. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol 1994; 12: 2447–52

    PubMed  CAS  Google Scholar 

  28. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385–90

    PubMed  CAS  Google Scholar 

  29. Silliman RA, Guadagnoli E, Weitberg AB, et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989; 44(2): 46–51

    Google Scholar 

  30. Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. JAMA 1987; 20: 2766–70

    Google Scholar 

  31. Kantorowitz DA, Poulter CA, Sischy B, et al. Treatment of breast cancer among elderly women with segmental mastectomy or segmental mastectomy plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15: 263–70

    PubMed  CAS  Google Scholar 

  32. Yancik R, Ries LG. Epidemiologic features of cancer in the elderly. In: Zenser TV, Coe RM, editors. Cancer and aging: progress in research and treatment. New York: Springer, 1989: 19–29

    Google Scholar 

  33. Kennedy BJ. Needed: clinical trials for older patients. J Clin Oncol 1991; 9: 718–20

    PubMed  CAS  Google Scholar 

  34. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153–8

    PubMed  CAS  Google Scholar 

  35. Denham MJ. The ethics of research in the elderly. Age Ageing 1984; 13: 321–7

    PubMed  CAS  Google Scholar 

  36. Zimmer AW, Calkins E, Hadley E, et al. Conducting research in geriatric populations. Ann Intern Med 1985; 103: 276–83

    PubMed  CAS  Google Scholar 

  37. Balducci L, Ades T, Carbone PP, et al. Issues in treatment. Cancer 1991; 68: 2527–9

    PubMed  CAS  Google Scholar 

  38. Sauer H. Zytostatikatherapie beim alten Menschen. Internist 1991; 32: 479–85

    PubMed  CAS  Google Scholar 

  39. Osoba D. Lessons learned from measuring health related quality of life in oncology. J Clin Oncol 1994; 12: 608–16

    PubMed  CAS  Google Scholar 

  40. Finlay IG, Dunlop R. Quality of life assessment in palliative care. Ann Oncol 1994; 5: 13–8

    PubMed  CAS  Google Scholar 

  41. Kahn SB, Houts PS, Harding SP. Quality of life and patients with cancer: a comparative study of patient versus physicians perceptions and its implications for cancer education. J Cancer Educ 1992; 7: 241–9

    PubMed  CAS  Google Scholar 

  42. Sarna L. Women with lung cancer: impact on quality of life. Qual Life Res 1993; 2: 13–22

    PubMed  CAS  Google Scholar 

  43. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md Med J 1965; 14: 61–5

    CAS  Google Scholar 

  44. Applegate WB, Blass JP, Williams TF. Instruments for the functional assessment of older patients. N Engl J Med 1990; 322: 1207–14

    PubMed  CAS  Google Scholar 

  45. Porzsolt F, Gaus W. Wirksamkeit und Nutzen medizinischer MaBnahmen: ein Beitrag zur Optimierung des Gesundheitssystems. Klinikarzt 1993; 22: 522–8

    Google Scholar 

  46. Porzsolt F. Klinische Okonomik - Eine Forderung der Gesellschaft an die Arzte. Munch med Wschr 1994; 136: 221–8

    Google Scholar 

  47. Coplan G. Mastery of stress: psychosocial aspects. Am J Psychiatry 1981; 138: 413–20

    Google Scholar 

  48. Goodwin JS, Hunt WC, Samet JM. A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. Arch Intern Med 1991; 151: 366–70

    PubMed  CAS  Google Scholar 

  49. Fries JF, Koop E, Beadle CE, et al., for the Health Project Consortium. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 1993; 329: 321–5

    PubMed  CAS  Google Scholar 

  50. Fuchs VR. ‘Though much is taken’: reflections on aging, health and medical care. Milbank Mem Fund Q Health Soc 1984; 62: 143–66

    PubMed  CAS  Google Scholar 

  51. Temkin-Greener H, Meiners MR, Petty EA, et al. The use and cost of health services prior to death: a comparison of the Medicare-only and the Medicare-Medicaid elderly populations. Milbank Q 1992; 70: 679–701

    PubMed  CAS  Google Scholar 

  52. Scitovsky AA. Medical care in the last twelve months of life: the relation between age, functional status, and medical care expenditures. Milbank Q 1988; 66: 640–60

    PubMed  CAS  Google Scholar 

  53. Roos NP, Shapiro E, Tate R. Does a small majority of elderly account for a majority of health care expenditures? A sixteen year perspective. Milbank Q 1989; 67: 347–69

    PubMed  CAS  Google Scholar 

  54. Schneiderman LJ, Kronick R, Kaplan RM, et al. Effects of offering advance directives on medical treatments and costs. Ann Intern Med 1992; 117: 599–606

    PubMed  CAS  Google Scholar 

  55. Rubens R. Approaches to palliation and its evaluation. In: Porzsolt F, guest editor. Goals of palliative cancer therapy. Cancer Treat Rev 1993; 19 Suppl. A: 67–72

  56. Greco PJ, Schulman KA, Lavizzo-Mourey R, et al. The patient self-determination act and the future of advance directives. Ann Intern Med 1991; 115: 639–43

    PubMed  CAS  Google Scholar 

  57. Emanuel LL, Barry MJ, Stoeckle JD, et al. Advance directives for medical care — a case for greater use. N Engl J Med 1991; 324: 889–95

    PubMed  CAS  Google Scholar 

  58. Podrid PJ. Resuscitation in the elderly: a blessing or a curse? Ann Intern Med 1989; 111: 193–5

    PubMed  CAS  Google Scholar 

  59. Hoelzer D. Acute lymphoblastic leukemia — progress in children, less in adults. N Engl J Med 1993; 329: 1343–4

    PubMed  CAS  Google Scholar 

  60. Whitely R, Hannah P, Holmes F. Survival in acute leukemia in elderly patients: no improvement in the 1980s. J Am Geriatr Soc 1990; 38: 527–30

    PubMed  CAS  Google Scholar 

  61. MacDonald N. Oncology and palliative care. In: Porzsolt F, guest editor. Goals of palliative cancer therapy. Cancer Treat Rev 1993; 19 Suppl. A: 29–42

  62. Denger LF, Sloan JA. Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 1992; 45: 941–50

    Google Scholar 

  63. Fallowfield L, Hall A, Maguire P, et al. Psychological effects of being offered choice of surgery for breast cancer. BMJ 1994; 309: 448

    PubMed  CAS  Google Scholar 

  64. Maher EJ. Palliative medicine today — a matter for concern. In: Porzsolt F, guest editor. Goals of palliative cancer therapy. Cancer Treat Rev 1993; 19 Suppl. A: 15–21

    Google Scholar 

  65. Rothenbacker D, Porzsolt F. Strength of Evidence in Clinical Trials (SECT). A tool to standardise the value of presented data. Submitted for publication

  66. Porzsolt F, Wirth A, Mayer-Steinacker R, et al., for the Interdisciplinary Oncology Conference, Cancer Center, University of Ulm (CC W). Quality assurance in palliative treatment: goals should be defined, specified, and monitored. Proceedings of the American Society of Clinical Oncology; 1994 May 14–17: Dallas: ASCO, 1994

    Google Scholar 

  67. Porzsolt F, Wirth A, Mayer-Steinacker R, et al. Quality assurance in oncology: definition of treatment goal and assessment of its achievement. Onkologie 1994; 17: 454–7

    Google Scholar 

  68. Osoba D. Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. In: Prozsolt F, guest editor. Goals of palliative cancer therapy. Cancer Treat Rev 1993; 19 Suppl. A: 43–52

    Google Scholar 

  69. Annas GJ. Informed consent, cancer, and truth in prognosis. N Engl J Med 1994; 330: 223–5

    PubMed  CAS  Google Scholar 

  70. Porzsolt F, Tannock I. Goals of palliative cancer therapy. J Clin Oncol 1993; 2: 378–81

    Google Scholar 

  71. Porzsolt F. Scope of the problem. In: Porzsolt F, guest editor. Goals of palliative cancer therapy. Cancer Treat Rev 1993; 19 Suppl. A:3-14

  72. Osoba D, Aaronson NK, Till JE. A practical guide for selecting quality-of-life measures in clinical trials and practice. In: Osoba D, editor. Effect of cancer on quality of life. Boca Raton: CRC Press, 1991: 89–104

    Google Scholar 

  73. Tcheckmedyian NS, Cella DF, guest editors. Quality of life in current oncology practice and research, appendix 1. Cancer 1990; 4: 209–30

    Google Scholar 

  74. Bullinger M, Kirchberger I, Porzsolt F. Der EORTC-Lebensqualitäts-Fragebogen QLQ C30 — Erste psychometrische Ergebnisse einer Querschnittsuntersuchung an älteren Personen. Z Gerontopsychologie Psychiatrie 1993; 6: 259–65

    Google Scholar 

  75. Porzsolt F, Kosa R, Gaus W. Analysis of psychometric properties of three instruments for assessment of quality of life or well being: QLQ C30, SF-36, and QWB-7. Submitted for publication

  76. Aaronson NK, Ahmedzai S, Bergman B, et al., for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76

    PubMed  CAS  Google Scholar 

  77. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36), I: conceptual framework and item selection. Med Care 1992; 30: 473–83

    PubMed  Google Scholar 

  78. World Health Organization Expert Committee Report. Cancer Pain Relief and Palliative Care. Technical Report Series 804. Geneva: World Health Organization, 1990

    Google Scholar 

  79. Doyle D, Hanks G, MacDonald N. Introduction. In: Doyle D, Hanks G, MacDonald N, editors. Oxford Textbook of. Palliative Medicine. Oxford: Oxford University Press, 1993: 3–8

    Google Scholar 

  80. Hagdorn DC. The Oregon priority-setting exercise: quality of life and public policy. Hastings Center Report 1991 (May–June)

  81. Cartwright A. The roel of hospitals in caring for people in the last years of their lives. Age Aging 1991; 20(4): 271–4

    CAS  Google Scholar 

  82. Tirelli U, Zagonel V, Serraino D, et al. Non-Hodgkin’s lymphoma in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer lymphoma group study. J Clin Oncol 1988; 6: 1708–13

    PubMed  CAS  Google Scholar 

  83. Zagonel V, Tirelli U, Carbone A. Treatment of non-Hodgkin’s lymphomas in the elderly [letter]. J Clin Oncol 1986; 4: 1866–7

    PubMed  CAS  Google Scholar 

  84. Binet JL, for the French cooperative group on CLL. When and how to treat elderly patients with chronic lymphocytic leukemia (CLL). Hematol Oncol 1993; 11 Suppl. 1: 38

    PubMed  Google Scholar 

  85. Bertini M, for the Italian Multiregional Non Hodgkin’s Lymphoma Study Group. Therapeutic strategies in intermediate grade lymphomas in elderly patients. Hematol Oncol 1993; 11 Suppl. 1: 52–8

    PubMed  Google Scholar 

  86. Haferlach T, Gassmann W, Uharek L, et al. Mitoxantrone, etoposide and prednisolone (NOVEP) in previously untreated elderly patients with Non-Hodgkin’s lymphoma (NHL) and as salvage therapy for refractory NHL. Onkologie 1994; 16: 440–5

    Google Scholar 

  87. Hoerni B, Sotto JJ, Eghbali H, et al. Non-Hodgkin’s malignant lymphomas in patients older than 80. Cancer 1988; 61: 2057–9

    PubMed  CAS  Google Scholar 

  88. Pileri A, Palumbo A, Boccadoro M. Multiple myeloma: a tailored therapy for elderly patients. Hematol Oncol 1993; 11 Suppl. 1: 67–72

    PubMed  Google Scholar 

  89. Alexanian R, Dimoupulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–90

    PubMed  CAS  Google Scholar 

  90. Porzsolt F, Demeter J. When should hairy cell leukemia be treated [letter]? Lancet 1990; 336: 1387–8

    PubMed  CAS  Google Scholar 

  91. Porzsolt F, Demeter J, Heimpel H. Functional criteria for staging and treatment of hairy cell leukemia. Onkologie 1991; 14: 44–8

    PubMed  CAS  Google Scholar 

  92. Damasio EE, Federico M, for the ICGHCL. The Italian experience in the treatment of HCL. Hematol Oncol 1993; 11 Suppl. 1: 42–9

    PubMed  Google Scholar 

  93. Brogden RN, Sorkin EM. Pentostatin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993; 46: 652–77

    PubMed  CAS  Google Scholar 

  94. Grem JL, King SA, Chun H, et al. Cardiac complications observed in elderly patients following 2′-deoxycoformycin therapy. Am J Hematol 1991; 38: 245–7

    PubMed  CAS  Google Scholar 

  95. Porzsolt F, Thoma I, Unsold M, et al. Platelet-adjusted interferon-dosage in the treatment of advanced hairy cell leukemia. Blut 1985; 51: 73–82

    PubMed  CAS  Google Scholar 

  96. Levis A, for the Piemonte Hodgkin’s Disease Register. Recent advances in the therapy of Hodgkin’s disease in elderly patients. Hematol Oncol 1993; 11 Suppl. 1: 78–84

    PubMed  Google Scholar 

  97. Gustavsson A. Hodgkin’s disease of the elderly: a different disease? Hematol Oncol 1993; 11 Suppl. 1: 73–6

    PubMed  Google Scholar 

  98. Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82–91

    PubMed  CAS  Google Scholar 

  99. De Bock R, van Hove W, van Hoof A, et al. Oral idarubicin for RAEB, RAEB-T, AL post MDS: a phase II open study. Lorenzini Foundation Symposium, No. 173, Milano 1988: 247

  100. Berrebi A, Polliack A. Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts. In: Büechner T, Schellong G, Hiddemann W, et al., editors. Haematology and blood transfusion. Acute leukemia, II: Prognostic factors and treatment strategies 1990; 33: 342–5

  101. Späth-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single centre over a 10-year period. Ann Hematol 1994; 69: 291–6

    PubMed  Google Scholar 

  102. Delannoy A, Ferrant A, Bosly A, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol 1990; 45: 90–3

    PubMed  CAS  Google Scholar 

  103. Taylor PR, Reid MM, Brown M, et al. Acute lymphoblastic leukemia in patients aged 60 years or over: a population based study of incidence and outcome. Blood 1992; 80: 1813–7

    PubMed  CAS  Google Scholar 

  104. Iscoe NA, Goel V, Wu K, et al. Variation in breast cancer surgery in Ontario. Can Med Assoc 1994; 150: 345–52

    CAS  Google Scholar 

  105. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–4

    PubMed  CAS  Google Scholar 

  106. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1–15

    Google Scholar 

  107. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993; 11: 29–35

    PubMed  CAS  Google Scholar 

  108. Porzsolt F, Mayer-Steinacker R, Eggl C. Effectiveness and utility of a second line treatment in metastatic breast cancer. Onkologie 1995, in press

  109. Habeshaw T, Paul J, Jones R, et al. Epirubicin at two dose levels with prednisolone as treatment of advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991; 9: 295–304

    PubMed  CAS  Google Scholar 

  110. Gundersen S, Kvinnsland S, Klepp O, et al. Weekly adriamycin versus VAC in advanced breast cancer: a randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1431–4

    PubMed  CAS  Google Scholar 

  111. Porzsolt F, Kreuser ED, Meuret G, et al. High-intensity therapy versus low-intensity therapy in advanced breast cancer patients. Cancer Treat Rev 1990; 17: 287–92

    PubMed  CAS  Google Scholar 

  112. Wilmanns W, Binsack T, Sauer H. Zytostatische Polychemotherapie im hoheren Lebensalter. Dtsch Med Wschr 1985; 110: 1959–62

    PubMed  CAS  Google Scholar 

  113. Carney DN, Grogan L, Smit EF, et al. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1990; 17 Suppl. 2: 49–53

    PubMed  CAS  Google Scholar 

  114. Allan SG, Gregor A, Cornbleet MA, et al. Phase II trial of vindesine and VP 16–213 in the palliation of poor prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol 1984; 13: 106–8

    PubMed  CAS  Google Scholar 

  115. Zagonel V, Pinto A, Serraino D, et al. Lung cancer in the elderly. Cancer Treat Rev 1994; 20: 315–29

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine III and Tumor Center Ulm, University of Ulm, Robert Koch Strasse 8, D-89081, Ulm, Germany

    Franz Porzsolt

  2. Chair of Internal Medicine and Gerontology, University of Erlangen-Nuremberg, Germany

    Joachim Zeeh & Dieter Platt

Authors
  1. Franz Porzsolt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joachim Zeeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dieter Platt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porzsolt, F., Zeeh, J. & Platt, D. Palliative Therapies in Elderly Cancer Patients. Drugs & Aging 6, 192–209 (1995). https://doi.org/10.2165/00002512-199506030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199506030-00003

Keywords

Search

Navigation